| Literature DB >> 31185601 |
Miklós Bege1, Alexandra Kiss2, Máté Kicsák3, Ilona Bereczki4, Viktória Baksa5, Gábor Király6, Gábor Szemán-Nagy7, M Zsuzsa Szigeti8, Pál Herczegh9, Anikó Borbás10.
Abstract
A small library of 3'-deoxy-C3'-substituted xylofuranosyl-pyrimidine nucleoside analogues were prepared by photoinducedEntities:
Keywords: cytostatic; genotoxic; radical thiol-ene coupling; squamous carcinoma cell line (SCC); time-lapse imaging video-microscopy; xylofuranosyl nucleoside
Mesh:
Substances:
Year: 2019 PMID: 31185601 PMCID: PMC6600393 DOI: 10.3390/molecules24112173
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Sugar modified nucleosides as approved (A) or clinically investigated (B) anticancer agents.
Figure 2Cytotoxic effects of the previously prepared 3’-deoxy-3’-C-modified β-d-xylofuranosyl-uracil (1 and 2) and –thymine (3–5) derivatives [19] on squamous cell carcinoma (SCC) and human keratinocyte (HaCaT) cell lines. (TBDMS: tert-butyldimethylsilyl).
Scheme 1Synthesis of 1-(3’-deoxy-3’-C-alkylthiomethyl-β-d-xylofuranosyl)thymine (5, 8–17 and 19) and 1-(3’-deoxy-3’-C-alkylthiomethyl-β-d-xylofuranosyl)uracil (2, 18) derivatives.
Photoinitiated additions of thiols onto 7T and 7U.
| Entry | R’ | Temperature | Product | d.r. a | R | Yield |
|---|---|---|---|---|---|---|
| 1 | Ethyl | −80 °C |
| 9:1 | Me | 86% |
| 2 | −80 °C |
| 13:1 | Me | 49% | |
| 3 | −40 to 0 °C |
| 33:1 | Me | 34% | |
| 4 | −80 to −40 °C |
| 20:1 | Me | 62% | |
| 5 | 0 °C |
| 10:1 | Me | 65% | |
| 6 | 0 °C |
| 22:1 | Me | 36% | |
| 7 | −80 to 0 °C |
| 14:1 | Me | 54% | |
| 8 | −80 to −40 °C |
| 30:1 | Me | 46% | |
| 9 | 0 °C |
| 24:1 | Me | 29% | |
| 10 | 0 °C |
| 22:1 | Me | 29% | |
| 11 | Phenyl | −80 °C −r.t. |
| - | Me | no reaction |
| 12 | Benzyl | −40 °C |
| 10:1 | Me | 82% |
| 13 | Hydroxyethyl | −80 °C |
| 3:1 | Me | 75% |
| 14 | Hydroxyethyl | −40 °C |
| 4:1 | Me | 72% |
| 15 | Hydroxyethyl | 0 °C |
| 4:1 | Me | 74% |
| 16 | −80 °C |
| 50:1 | H | 75% | |
| 17 | −40 °C |
| 60:1 | H | 59% | |
| 18 | 0 °C |
| 12:1 | H | 66% |
DMPA: 2,2-dimethoxy-2-phenylacetophenone; THF: tetrahydrofuran; a The D-xylo:D-ribo ratio was determined by 1H-NMR.
Characteristic 1H and 13C NMR peaks (ppm) and 3JH,H values (Hz) of compounds 8–18 and reference compounds 3 and 3-.
| Compound | R | NB | H-1’ | H-4’ | H-2’ | H-3’ | C-1’ | C-3’ |
|---|---|---|---|---|---|---|---|---|
|
| GlcPerAc | T | 5.81, d | 4.22–4.17 | 4.42, dd | 2.45–2.38 | 90.7 | 41.6 |
| m b | m | |||||||
|
| GlcPerAc | T | 5.92, d | 4.33, d | 4.10, dd | 2.80–2.76 | 87.1 | 47.5 |
| m | ||||||||
|
| Ethyl | T | 6.12, d | N. A. | N. A. | 3.01–2.94 | 87.4 | 46.5 |
| m | ||||||||
|
| T | 6.10, d | 4.44, d | 4.28, dd | 2.82, td | 87.2 | 46.9 | |
|
| T | 6.11, d | 4.46, d | 4.28, dd | 2.94–2.98 | 87.2 | 46.5 | |
| m | ||||||||
|
| T | 6.12, d | 4.48, d | 4.29, dd | 3.02–2.79 | 87.3 | 46.7 | |
| m | ||||||||
|
| T | 6.10, d | 4.41, d | 4.29, dd | 2.87–2.76 | 87.2 | 48 | |
| m | ||||||||
|
| T | 6.12, d | 4.46, d | 4.29, dd | 2.89–2.79 | 87.3 | 46.5 | |
| m | ||||||||
|
| T | 6.12, d | 4.46, d | 4.29, dd | 2.73–2.63 | 87.3 | 46.5 | |
| m | ||||||||
|
| T | 6.12, d | 4.47, d | 4.29, dd | N. A. | 87.3 | 46.5 | |
|
| Benzyl | T | 6.10, d | N. A. | N. A. | 2.88–2.75 b | 87.1 | 45.8 |
| m | ||||||||
|
| Hydroxyethyl | T | 6.09, d | 4.48, d | N. A. | N. A. | 87.4 | 46.7 |
|
| U | 6.13, d | N. A. | N. A. | 2.95–2.79 | 87.7 | 46.6 | |
| m |
a: Data are taken from Ref. [31], b: overlapping signals, N. A.: not assigned due to the overlapping signals, NB: nucleobase (T: thymine, U: uracil).
Scheme 2Deprotection of 8.
Cytotoxic activity of the modified nucleoside derivatives.
| Compound | R | HaCaT IC50 a | SCC IC50 a | logP b | SI c |
|---|---|---|---|---|---|
|
| GlcPerAc | - d | - d | 3.83 | |
|
| 12.6 ± 0.22 | 11.8 ± 0.22 | 5.82 | 1.07 | |
|
| GlcPerAc | 22.4±2.91 | - d | 4.11 | |
|
| MannPerAc | - d | - d | 4.11 | |
|
| 22.2 ± 1.70 | 15.2 ± 1.00 | 6.10 | 1.46 | |
|
| Ethyl | 16.9 ± 0.55 | 15.5 ± 0.59 | 5.63 | 1.09 |
|
| 22.7 ± 1.34 | 15.2 ± 0.48 | 5.93 | 1.49 | |
|
| 27.9 ± 1.85 | 17.0 ± 1.55 | 6.49 | 1.64 | |
|
| 15.5 ± 2.14 | 23.5 ± 0.12 | 6.50 | 0.66 | |
|
| >34.9 | 31.1 ± 0.79 | 5.90 | 1.12 | |
|
| 22.9 ± 0.57 | 15.9 ± 0.32 | 7.28 | 1.44 | |
|
| 26.4 ± 0.37 | 26.0 ± 0.76 | 8.08 | 1.02 | |
|
| - d | - d | 9.66 | ||
|
| Benzyl | 14.3 ± 0.36 | 14.6 ± 0.19 | 7.06 | 0.98 |
|
| Hydroxyethyl | 14.6 ± 0.82 | 16.0 ± 0.17 | 4.40 | 0.91 |
|
| 14.4 ± 1.59 | 10.9 ± 0.18 | 6.21 | 1.32 | |
|
| Ethyl | - d | - d | −0.10 | |
|
| - | 15.6 ± 4.45 | 18.8 ± 0.74 | 3.81 | 0.83 |
|
| - | 290.4 ± 2.76 | 215.6 ± 2.33 | ||
|
| - | 60.7 ± 8.45 |
a: µM, b: calculated (see more in Experimental section), c: selectivity index = HaCaT IC50/SCC IC50) d: no cytotoxicity at the highest test concentration of 20 µg/mL; e: positive control; f: 5-FU (5-fluorouracil): positive control, IC50 value is taken from Ref. [36].
Figure 3Correlation diagram indicating selectivity: IC50 values for SCC cells are plotted against IC50 values for HaCaT cells.
The effect of compound 10 on the size of mother cells.
| Size of Control Cells (µm2) | DMSO Control Cells Size (µm2) | Treated Cells Size (µm2) a | Treated/DMSO Difference (%) b | |
|---|---|---|---|---|
|
| 22.81 ± 1.13 | 23.48 ± 1.87 | 21.60 ± 1.93 | −9.00 |
|
| 17.75 ± 1.09 | 19.00 ± 1.09 | 21.44 ± 1.42 | 12.80 |
a: treated with 17.0 µM solution of compound 10, b: (treated cells size/DMSO controll cell size)*100-100.
Figure 4Effect of DMSO and compound 10 (17.0 µM) on the mother cell sizes of HaCaT and SCC cells.
The effect of compound 10 on the generation times of the cells.
| Control Gen. Time (h) | DMSO Control Gen. Time (h) | Treated Cells a Gen. Time (h) | Treated/DMSO Difference (%) | |
|---|---|---|---|---|
|
| 16.37 ± 0.092 | 17.11 ± 1.10 | 21.67 ± 1.01 | 20.80 |
|
| 11.04 ± 0.56 | 13.57 ± 0.91 | >48.00 | - |
a: treated with 17.0 µM solution of compound 10.
Figure 5Effect of DMSO and compound 10 on the generation time of HaCaT and SCC cells. *: No division within 48 h.
Figure 6Effect of DMSO and compound 10 on confluency of HaCaT and SCC cells.
Figure 7Nucleus of HaCaT cells stained by DAPI. (A) DMSO control, (B) treated with 17.0 µM of compound 10.
Figure 8Nucleus of SCC cells stained by DAPI. (A) DMSO control, (B) treated with 17.0 µM of compound 10.